Table 4. Adverse reactions of different types of vaccines and the relationship between different treatment regimens and adverse reactions.
| Adverse reactions | Total (n=341) | Type of vaccination | Current treatment | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactivated vaccine (n=289, 84.8%) | Protein subunit vaccine (n=52, 15.2%) | P | CT (n=15) | TT (n=2) | ET (n=221) | CMT (n=20) | ≥ Two therapy methods (n=7) | NT (n=76) | P | |||
| Any | 147 (43.1) | 124 (42.9) | 23 (44.2) | 0.859 | 6 (40.0) | 0 | 101 (45.7) | 8 (40.0) | 3 (42.9) | 29 (38.2) | 0.781 | |
| Local | 115 (33.7) | 95 (32.9) | 20 (38.5) | 0.433 | 4 (26.7) | 0 | 81 (36.7) | 3 (15.0) | 2 (28.6) | 25 (32.9) | 0.414 | |
| Pain | 97 (28.4) | 83 (28.7) | 14 (26.9) | 0.791 | 3 (20.0) | 0 | 69 (31.2) | 2 (10.0) | 1 (14.3) | 22 (28.9) | 0.339 | |
| Induration, swelling | 18 (5.3) | 13 (4.5) | 5 (9.6) | 0.168 | 0 | 0 | 12 (5.4) | 1 (5.0) | 1 (14.3) | 4 (5.3) | 0.666 | |
| Itch | 14 (4.1) | 10 (3.5) | 4 (7.7) | 0.243 | 1 (6.7) | 0 | 8 (3.6) | 0 | 0 | 5 (6.6) | 0.630 | |
| Systemic | 52 (15.2) | 45 (15.6) | 7 (13.5) | 0.697 | 3 (20.0) | 0 | 33 (14.9) | 17 (85.0) | 1 (14.3) | 10 (13.2) | <0.001 | |
| Fatigue | 30 (8.8) | 28 (9.7) | 2 (3.8) | 0.284 | 3 (20.0) | 0 | 21 (9.5) | 2 (10.0) | 0 | 4 (5.3) | 0.457 | |
| Headache, dizziness | 11 (3.2) | 8 (2.8) | 3 (5.8) | 0.227 | 1 (6.7) | 0 | 5 (2.3) | 2 (10.0) | 0 | 3 (3.9) | 0.227 | |
| Stuffy, runny nose | 9 (2.6) | 8 (2.8) | 1 (1.9) | 1.000 | 0 | 0 | 5 (2.3) | 2 (10.0) | 0 | 2 (2.6) | 0.373 | |
| Itch | 7 (2.1) | 6 (2.1) | 1 (1.9) | 1.000 | 1 (6.7) | 0 | 5 (2.3) | 0 | 1 (14.3) | 0 | 0.099 | |
| Rash | 3 (0.9) | 2 (0.7) | 1 (1.9) | 0.392 | 0 | 0 | 2 (0.9) | 0 | 0 | 1 (1.3) | 1.000 | |
| Arthralgia | 3 (0.9) | 2 (0.7) | 1 (1.9) | 0.392 | 0 | 0 | 2 (0.9) | 1 (5.0) | 0 | 0 | 0.406 | |
| Fever | 3 (0.9) | 2 (0.7) | 1 (1.9) | 0.392 | 0 | 0 | 2 (0.9) | 1 (5.0) | 0 | 0 | 0.406 | |
| Diarrhea | 2 (0.6) | 2 (0.7) | 0 | 1.000 | 0 | 0 | 2 (0.9) | 0 | 0 | 0 | 1.000 | |
| Appetite impaired | 2 (0.6) | 2 (0.7) | 0 | 1.000 | 0 | 0 | 1 (0.5) | 1 (5.0) | 0 | 0 | 0.291 | |
| Other | 6 (1.8) | 6 (2.1) | 0 | 0.596 | 1 (6.7) | 0 | 4 (1.8) | 0 | 0 | 1 | 0.513 | |
The data are expressed as n (%). CT, chemotherapy; TT, HER2-targeted therapy (such as trastuzumab, pertuzumab, and pyrotinib, among others); ET, endocrine therapy (such as tamoxifen, toremifene, anastrozole, exemestane); CMT, Chinese medicine treatment; NT, not receiving a treatment.